TAXUS Liberté Attenuates the Risk of Restenosis in Patients With Medically Treated Diabetes Mellitus
Results From the TAXUS ATLAS Program
Ehtisham Mahmud, John A. Ormiston, Mark A. Turco, Jeffrey J. Popma, Neil J. Weissman, Charles D. O'Shaughnessy, Tift Mann, Jack J. Hall, Thomas F. McGarry, Louis A. Cannon, Mark W.I. Webster, Lazar Mandinov and Donald S. Baim
Frequency of percent diameter stenosis (A) and binary restenosis (B) 5 mm proximal and distal to each stent edge in subjects with and without diabetes mellitus treated with the TAXUS Liberté Stent in TAXUS ATLAS studies. Intent-to-treat, angiographic subset (n = 1,201; diabetic: 334; nondiabetic: 867).